Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

Patients with relapsed/refractory (R/R) peripheral T-cell lymphoma (PTCL) have a poor prognosis, with an expected survival of less than 1 year using standard salvage therapies. Recent advances in our understanding of the biology of PTCL have led to identifying B-Cell Lymphoma 2 (BCL2) protein as a p...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballotta, Laura, Zinzani, Pier Luigi, Pileri, Stefano, Bruna, Riccardo, Tani, Monica, Casadei, Beatrice, Tabanelli, Valentina, Volpetti, Stefano, Luminari, Stefano, Corradini, Paolo, Lucchini, Elisa, Tisi, Maria Chiara, Merli, Michele, Re, Alessandro, Varettoni, Marzia, Pesce, Emanuela Anna, Zaja, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685372/
https://www.ncbi.nlm.nih.gov/pubmed/34938664
http://dx.doi.org/10.3389/fonc.2021.789891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685372/
https://www.ncbi.nlm.nih.gov/pubmed/34938664
http://dx.doi.org/10.3389/fonc.2021.789891

Ejemplares similares